A376930 Stock Overview
Engages in the in vitro diagnosis and remote diagnosis business worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Noul Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,210.00 |
| 52 Week High | ₩8,520.00 |
| 52 Week Low | ₩2,040.00 |
| Beta | -0.32 |
| 11 Month Change | -14.01% |
| 3 Month Change | -7.53% |
| 1 Year Change | -11.16% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| A376930 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -4.3% | -3.2% | -1.4% |
| 1Y | -11.2% | 14.0% | 0.1% |
Return vs Industry: A376930 underperformed the KR Medical Equipment industry which returned 14% over the past year.
Return vs Market: A376930 underperformed the KR Market which returned 0.1% over the past year.
Price Volatility
| A376930 volatility | |
|---|---|
| A376930 Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 5.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A376930's share price has been volatile over the past 3 months.
Volatility Over Time: A376930's weekly volatility has decreased from 14% to 9% over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 117 | David Lim | www.noul.kr |
Noul Co.,Ltd. engages in the in vitro diagnosis and remote diagnosis business worldwide. It offers miLab, an AI-based blood diagnostic medical device that automates sample preparation, imaging, and analysis.
Noul Co.,Ltd. Fundamentals Summary
| A376930 fundamental statistics | |
|---|---|
| Market cap | ₩81.65b |
| Earnings (TTM) | -₩16.54b |
| Revenue (TTM) | ₩2.26b |
36.1x
P/S Ratio-4.9x
P/E RatioIs A376930 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A376930 income statement (TTM) | |
|---|---|
| Revenue | ₩2.26b |
| Cost of Revenue | ₩2.23b |
| Gross Profit | ₩30.40m |
| Other Expenses | ₩16.57b |
| Earnings | -₩16.54b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -447.74 |
| Gross Margin | 1.34% |
| Net Profit Margin | -731.16% |
| Debt/Equity Ratio | 3.1% |
How did A376930 perform over the long term?
See historical performance and comparison